Lycopene and gene expression in benign prostate: a phase II randomized trial

被引：1
|
作者：
Gann, Peter H. [1 ]
Dai, Yang [1 ]
Giangreco, Angeline Antonio [1 ]
Deaton, Ryan [1 ]
van Breemen, Richard [1 ]
Lu, Yi [1 ]
Rueter, Erika Enk [1 ]
Nonn, Larisa [1 ]
机构：
[1] Univ Illinois, Chicago, IL USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-LB-217
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-217
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I/II clinical trial of gene therapy for hormone refractory metastatic prostate cancer
    Gotoh, A
    Terao, S
    Shirakawa, T
    JOURNAL OF GENE MEDICINE, 2006, 8 (03): : 371 - 372
  • [22] Seamlessly expanding a randomized phase II trial to phase III
    Inoue, LYT
    Thall, PF
    Berry, DA
    BIOMETRICS, 2002, 58 (04) : 823 - 831
  • [23] Randomized phase II trial of docetaxel, with or without doxercalciferol, in advanced, androgen-independent prostate cancer
    Attia, S.
    Eickhoff, J.
    Wilding, G.
    Blank, J.
    Rezazadeh, H.
    Shevrin, D.
    Glode, M.
    Jumonville, A.
    Eastman, M.
    Liu, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer
    Figg, WD
    Arlen, P
    Gulley, J
    Fernandez, P
    Noone, M
    Fedenko, K
    Hamilton, M
    Parker, C
    Kruger, EA
    Pluda, J
    Dahut, WL
    SEMINARS IN ONCOLOGY, 2001, 28 (04) : 62 - 66
  • [25] A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)
    Tran, Phuoc T.
    Phillips, Ryan
    Shi, William
    Lim, Su Jin
    Antonarakis, Emmanuel S.
    Rowe, Steven P.
    Ross, Ashley
    Gorin, Michael A.
    Deville, Curtiland
    Greco, Stephen C.
    Paller, Channing Judith
    DeWeese, Theodore L.
    Song, Daniel Y.
    Wang, Hao
    Carducci, Michael Anthony
    Pienta, Kenneth J.
    Pomper, Martin
    Dicker, Adam P.
    Eisenberger, Mario A.
    Diehn, Maximilian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [26] Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer
    Vadim S. Koshkin
    Maria C. Mir
    Pedro Barata
    Anita Gul
    Ruby Gupta
    Andrew J. Stephenson
    Jihad Kaouk
    Ryan Berglund
    Cristina Magi-Galluzzi
    Eric A. Klein
    Robert Dreicer
    Jorge A. Garcia
    Investigational New Drugs, 2019, 37 : 559 - 566
  • [27] Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
    Molife, L. Rhoda
    Omlin, Aurelius
    Jones, Rob J.
    Karavasilis, Vasilios
    Bloomfield, David
    Lumsden, Graeme
    Fong, Peter C.
    Olmos, David
    O'Sullivan, Joe M.
    Pedley, Ian
    Hickish, Tamas
    Jenkins, Peter
    Thompson, Emilda
    Oommen, Nikhil
    Wheatley, Duncan
    Heath, Catherine
    Temple, Graham
    Pelling, Katy
    de Bono, Johann S.
    FUTURE ONCOLOGY, 2014, 10 (02) : 219 - 231
  • [28] PEACE V - STORM randomized phase II trial for oligorecurrent nodal prostate cancer: acute toxicity
    Zilli, T.
    Siva, S.
    Heikkila, R.
    Dirix, P.
    Liefhooghe, N.
    Otte, F.
    Gomez-Iturriaga, A.
    Everaerts, W.
    Shelan, M.
    Conde-Moreno, A.
    Campos, F. Lopez
    Papachristofilou, A.
    Guckenberger, M.
    Scorsetti, M.
    Zapatero, A.
    Iturre, A. Villafranca
    Eito, C.
    Counago, F.
    Muto, P.
    Van De Voorde, L.
    Fonteyne, V.
    Moon, D.
    Thon, K.
    Mercier, C.
    Achard, V.
    Stellamans, K.
    Goetghebeur, E.
    Reynders, D.
    Ost, P.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S528 - S529
  • [29] Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer
    Koshkin, Vadim S.
    Mir, Maria C.
    Barata, Pedro
    Gul, Anita
    Gupta, Ruby
    Stephenson, Andrew J.
    Kaouk, Jihad
    Berglund, Ryan
    Magi-Galluzzi, Cristina
    Klein, Eric A.
    Dreicer, Robert
    Garcia, Jorge A.
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (03) : 559 - 566
  • [30] A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer
    Figg, WD
    Dahut, W
    Duray, P
    Hamilton, M
    Tompkins, A
    Steinberg, SM
    Jones, E
    Premkumar, A
    Linehan, WM
    Floeter, MK
    Chen, CC
    Dixon, S
    Kohler, DR
    Krüger, EA
    Gubish, E
    Pluda, JM
    Reed, E
    CLINICAL CANCER RESEARCH, 2001, 7 (07) : 1888 - 1893
12345